Trial Profile
GEM-CLARIDEX: Lenalidomide and Dexamethasone (Ld) Versus Clarithromycin / Lenalidomide [Revlimid] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Clarithromycin; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms GEM-CLARIDEX
- 13 Dec 2022 Results of an analysis assessing immune biomarkers in elderly newly diagnosed multiple myeloma patients treated with Lenalidomide and Dexamethasone presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 17 Jan 2022 Planned primary completion date changed from 1 May 2021 to 1 Oct 2024.
- 14 Apr 2021 Planned End Date changed from 1 Jan 2022 to 10 Oct 2024.